Home > Cardiology > ACC 2021 > Valvular Heart Disease > Apixaban outcomes similar to current standard of care following TAVR

Apixaban outcomes similar to current standard of care following TAVR

Presented By
Prof. Jean-Philippe Collet, Sorbonne Université, France
Conference
ACC 2021
Trial
ATLANTIS
The bleeding safety profile of apixaban was similar to that of the current standard of care, and the net clinical benefit of administering apixaban following transcatheter aortic valve replacement (TAVR) was not superior to current standard-of-care antithrombotic approaches in the ATLANTIS trial [1]. Prof. Jean-Philippe Collet (Sorbonne Université, France) presented results of the multicentre, phase 3, prospective, open-label, randomised ATLANTIS (NCT02664649) trial. ATLANTIS sought to compare the efficacy of apixaban, an anti-Xa, direct oral anticoagulant, with the current standard of care in patients who had undergone TAVR. The investigators randomised 1,510 participants to receive either apixaban (n=749) twice daily or usual care (n=751) for 1 year following TAVR. Randomisation was stratified according to the presence...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on